D2-blockade and possible ziprasidone-induced galactorrhea.
This is the second report of possible ziprasidone-induced galactorrhea in an adult female. This case illustrates the need to consider dose as well as potency when interpreting the response of a patient to a drug, particularly when the response appears to be idiosyncratic.
Ramadan
Mohamed
M
Department of Psychiatry, School of Medicine, University of Kansas, Wichita, KS 67214, USA. ibramadan@yahoo.com
Khan
Ahsan
A
Preskorn
Sheldon
S
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003865:Major Depressive Disorder / Q000188:drug therapy; D018492:Dopamine Antagonists / Q000009:adverse effects*; D065127:Dopamine D2 Receptor Antagonists; D005687:Galactorrhea / Q000139:chemically induced*; D006801:Humans; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011569:Psychiatric Status Rating Scales; D013844:Thiazoles / Q000009:adverse effects* / Q000627:therapeutic use
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D065127:Dopamine D2 Receptor Antagonists; D010879:Piperazines; D013844:Thiazoles; C092292:ziprasidone